MedPath

UNIVERSITY OF SOUTHERN CALIFORNIA

UNIVERSITY OF SOUTHERN CALIFORNIA logo
🇺🇸United States
Ownership
Private
Established
1880-01-01
Employees
10K
Market Cap
-
Website
http://startusc.com

Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy

Completed
Conditions
Breast Carcinoma
Cancer Survivor
Interventions
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2015-09-09
Last Posted Date
2019-10-23
Lead Sponsor
University of Southern California
Target Recruit Count
100
Registration Number
NCT02545023
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Fish Oil Brain Delivery Study

Phase 2
Completed
Conditions
Brain Health
Interventions
Dietary Supplement: Docosahexaenoic acid
First Posted Date
2015-09-04
Last Posted Date
2020-03-31
Lead Sponsor
University of Southern California
Target Recruit Count
31
Registration Number
NCT02541929
Locations
🇺🇸

USC Keck School of Medicine, Los Angeles, California, United States

Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

Not Applicable
Active, not recruiting
Conditions
Lymphadenopathy
Stage I Testicular Seminoma
Stage II Testicular Seminoma
Interventions
Other: Laboratory Biomarker Analysis
Procedure: Retroperitoneal Lymph Node Dissection
First Posted Date
2015-09-01
Last Posted Date
2024-03-18
Lead Sponsor
University of Southern California
Target Recruit Count
55
Registration Number
NCT02537548
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

University of Colorado Hospital - Aurora, Aurora, Colorado, United States

🇺🇸

Stanford University Hospitals & Clinics, Stanford, California, United States

and more 11 locations

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Phase 4
Terminated
Conditions
HIV
Contraception
Interventions
First Posted Date
2015-08-24
Last Posted Date
2019-05-31
Lead Sponsor
University of Southern California
Target Recruit Count
17
Registration Number
NCT02531321
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use

Phase 4
Withdrawn
Conditions
Compliance
Overactive Bladder
Xerostomia
Interventions
Drug: Biotene oral spray
First Posted Date
2015-08-13
Last Posted Date
2018-07-12
Lead Sponsor
University of Southern California
Registration Number
NCT02522936

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
Interventions
Drug: Bortezomib
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Wild-type Reovirus
First Posted Date
2015-08-03
Last Posted Date
2023-08-14
Lead Sponsor
University of Southern California
Target Recruit Count
14
Registration Number
NCT02514382
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer

Withdrawn
Conditions
Stage II Bladder Urothelial Carcinoma
Interventions
Procedure: Catheter Management
Other: Cytology Specimen Collection Procedure
Other: Laboratory Biomarker Analysis
First Posted Date
2015-08-03
Last Posted Date
2018-01-02
Lead Sponsor
University of Southern California
Registration Number
NCT02514408

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

Phase 4
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: Ceftazidime/avibactam
First Posted Date
2015-07-22
Last Posted Date
2018-11-27
Lead Sponsor
University of Southern California
Target Recruit Count
12
Registration Number
NCT02504827
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1
Terminated
Conditions
Head and Neck Squamous Cell Carcinoma
Metastatic Pancreatic Adenocarcinoma
Non-Resectable Cholangiocarcinoma
Unresectable Pancreatic Cancer
Pancreatic Adenocarcinoma
Recurrent Gallbladder Carcinoma
Recurrent Non-Small Cell Lung Carcinoma
Stage III Pancreatic Cancer
Stage IIIA Gallbladder Cancer
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Drug: Gemcitabine Hydrochloride
Drug: Docetaxel
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Other: Pharmacological Study
Biological: Recombinant EphB4-HSA Fusion Protein
First Posted Date
2015-07-13
Last Posted Date
2023-08-14
Lead Sponsor
University of Southern California
Target Recruit Count
61
Registration Number
NCT02495896
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer

Terminated
Conditions
Stage I Bladder Cancer With Carcinoma In Situ
Stage I Bladder Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma
Stage 0a Bladder Urothelial Carcinoma
Stage 0is Bladder Urothelial Carcinoma
Stage IV Bladder Urothelial Carcinoma
Bladder Papillary Urothelial Carcinoma
Interventions
Other: Laboratory Biomarker Analysis
First Posted Date
2015-07-10
Last Posted Date
2019-07-08
Lead Sponsor
University of Southern California
Target Recruit Count
4
Registration Number
NCT02494635
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath